<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aim of this study was to determine the safety, tolerance and efficacy of linezolid for the treatment of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> from <z:mp ids='MP_0001796'>Gram-positive</z:mp> bacteria in immunocompromised children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was a prospective non-comparative unblinded study in the Hematology/<z:hpo ids='HP_0002664'>Oncology</z:hpo> Unit over a two-year period, administering linezolid as monotherapy in children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Seventeen children received linezolid (30 mg/kgr: 3 i.v. per day) </plain></SENT>
<SENT sid="3" pm="."><plain>Mean duration of linezolid administration was 12.2 days (range, 6-38 days), while the median age of the evaluable patients was 2.2 years (range, 6 months-11.2 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Primary diagnosis was <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (nine patients), <z:mp ids='MP_0009277'>brain tumor</z:mp> (three patients), multi-organ <z:mpath ids='MPATH_653'>Langerhans cell histiocytosis</z:mpath> (two patients), <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:mp ids='MP_0008000'>ovarian tumor</z:mp> (one patient each) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were in the midst of chemotherapy cycles </plain></SENT>
<SENT sid="6" pm="."><plain>Ten out of 17 children had positive blood cultures (<z:chebi fb="0" ids="6827">methicillin</z:chebi>-resistant Staphylococcus aureus, four patients; <z:chebi fb="0" ids="28001">vancomycin</z:chebi>-resistant Enterococcus, three patients; <z:chebi fb="93" ids="17334">penicillin</z:chebi>-resistant Streptococcus pneumoniae, three patients), while seven of the 17 had <z:hpo ids='HP_0001945'>fever</z:hpo> and <z:chebi fb="0" ids="28001">vancomycin</z:chebi>-resistant Enterococcus in stool cultures </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were considered clinically cured after the end of the linezolid regimen (100% efficacy) </plain></SENT>
<SENT sid="8" pm="."><plain>The main adverse events were <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> grade 1-3 and <z:hpo ids='HP_0001903'>anemia</z:hpo> grade 2-3 (four and two patients, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Chemotherapy-induced myelotoxicity (six patients) was not worsened during linezolid therapy </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:mp ids='MP_0001914'>bleeding</z:mp> episodes were presented </plain></SENT>
<SENT sid="11" pm="."><plain>Self-limited <z:hpo ids='HP_0002014'>diarrhea</z:hpo> grade 1-2 was presented in four patients (mean duration 2 days) </plain></SENT>
<SENT sid="12" pm="."><plain>The total adverse event rate was 23.5%; however, there was no premature cessation of linezolid in any patient </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Linezolid may be another effective and safe therapy to treat <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> from resistant <z:mp ids='MP_0001796'>Gram-positive</z:mp> bacteria in immunocompromised children, even in young ages </plain></SENT>
</text></document>